Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Calgary
$150,000.00
Obesity risk and early life antibiotic/prebiotic exposure
EF 2015-16
Résumé
Antibiotics are life-saving drugs that have considerably reduced the rates of human death and disease. Their use was thought to have minimal risk to long-term health, but recent research suggests otherwise. Taking antibiotics early in life changes our intestinal bacteria thereby increasing the risk of obesity later in life. Early life exposure to antibiotics (during pregnancy and/or in the first year of life) is especially important because a stable bacterial community has not yet developed in an infant and the susceptibility to long-term problems is higher. One potential strategy to protect the intestinal bacteria during antibiotic treatment is to consume prebiotics, which are non-digestible food ingredients that selectively feed health-promoting bacteria in the intestine. Their intake reduces body fat and improves metabolic health. Given the current epidemic of childhood obesity (nearly one in three children in Canada are overweight/obese) and the high prevalence of infant antibiotic exposure (3 courses by the age of 2 years), studies are needed to develop strategies to reduce the chance for harm, especially when early life antibiotic exposure cannot be avoided. My work is novel as it will test whether giving prebiotics at the same time as antibiotics can reduce the risk of obesity from early life antibiotic exposure.
My initial study will focus on mothers and determine if obesity risk in offspring can be reduced when pregnant rats are given prebiotics at the same time as antibiotic treatment. My second study will focus on infancy and whether giving prebiotics directly to young rats can protect them from obesity associated with early antibiotic exposure. Overall, this work has the potential identify a dietary factor, prebiotics, as a novel therapy for reducing the burden of obesity and improving long-term health in Canada and worldwide. This work is in direct line with CIHR's strategic plan to capture innovation to produce better health and health care.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
339771
Name
Klancic Teja
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Obesity risk and early life antibiotic/prebiotic exposure
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Animal Models; Antibiotics; Endocrinology; Gut Microbiota; Inflammation; Maternal Programming; Metabolic Syndrome; Obesity; Prebiotics
Abstract
Antibiotics are life-saving drugs that have considerably reduced the rates of human death and disease. Their use was thought to have minimal risk to long-term health, but recent research suggests otherwise. Taking antibiotics early in life changes our intestinal bacteria thereby increasing the risk of obesity later in life. Early life exposure to antibiotics (during pregnancy and/or in the first year of life) is especially important because a stable bacterial community has not yet developed in an infant and the susceptibility to long-term problems is higher. One potential strategy to protect the intestinal bacteria during antibiotic treatment is to consume prebiotics, which are non-digestible food ingredients that selectively feed health-promoting bacteria in the intestine. Their intake reduces body fat and improves metabolic health. Given the current epidemic of childhood obesity (nearly one in three children in Canada are overweight/obese) and the high prevalence of infant antibiotic exposure (3 courses by the age of 2 years), studies are needed to develop strategies to reduce the chance for harm, especially when early life antibiotic exposure cannot be avoided. My work is novel as it will test whether giving prebiotics at the same time as antibiotics can reduce the risk of obesity from early life antibiotic exposure.
My initial study will focus on mothers and determine if obesity risk in offspring can be reduced when pregnant rats are given prebiotics at the same time as antibiotic treatment. My second study will focus on infancy and whether giving prebiotics directly to young rats can protect them from obesity associated with early antibiotic exposure. Overall, this work has the potential identify a dietary factor, prebiotics, as a novel therapy for reducing the burden of obesity and improving long-term health in Canada and worldwide. This work is in direct line with CIHR's strategic plan to capture innovation to produce better health and health care.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Klancic, Teja
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~